signal peptide peptidase like 2AGenealiases: IMD86 · IMP3 · PSL2
Q-omics provides the consensus-scored SPPL2A profile across patient tissues and cancer cell-line models. SPPL2A expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, SPPL2A is differentially expressed in 12, with the highest sampling consensus in COAD. Additionally, SPPL2A RNA expression shows 19,973 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight UVM, COAD, and ACC as cancer lineages where SPPL2A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SPPL2A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SPPL2A survival associations across molecular data types. SPPL2A RNA expression shows survival associations in the most cancer types (25), followed by mutation status (5) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SPPL2A RNA expression–survival associations across cancer types. High SPPL2A expression shows unfavorable associations in UVM, CESC, LGG, ACC and KIRP, but favorable associations in KIRC. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for SPPL2A RNA expression.
This table summarizes SPPL2A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 5. The strongest signals are observed in COAD for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for SPPL2A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SPPL2A shows lower tumor expression in COAD, THCA, KIRC and KICH and higher tumor expression in HNSC and LIHC. The COAD box plot shows higher SPPL2A RNA expression in normal versus tumor tissue (log2 FC = −1.654, t-test p < 0.001).
This table shows molecular features associated with SPPL2A in patient tissues and cancer cell lines. In patient samples, SPPL2A shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, SPPL2A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and UPPER_AERODIGESTIVE_TRACT.
